-
Geron Shares Seen Range-Bound On Lack Of Major Data Until Late 2017
Friday, August 19, 2016 - 12:28pm | 360Read More...BTIG expects Geron Corporation (NASDAQ: GERN) shares to be range-bound until major data release, potentially in late 2017 or 2018. Geron's lead compound imetelstat, an inhibitor of telomerase partnered with Johnson & Johnson (NYSE: JNJ)'s Janssen showed impressive activity in multiple...
-
BTIG Sets $12 Price Target On Rockwell Medical, Sees 63% Upside
Friday, August 19, 2016 - 12:13pm | 324Read More...BTIG has started coverage on Rockwell Medical Inc (NASDAQ: RMTI) with a Buy and a price target of $12, saying that its lead asset, Triferic, has the potential to replace IV iron in hemodialysis patients. Triferic is indicated to replace iron and maintain hemoglobin in hemodialysis patients versus...
-
Why This Analyst Is Awaiting More Efficacy Signals For Agios Pharma Candidates
Friday, August 19, 2016 - 11:59am | 319Read More...BTIG analyst Ling Wang initiated coverage on Agios Pharmaceuticals Inc (NASDAQ: AGIO) shares with a Neutral rating, citing balanced risk/reward at current levels. The brokerage is waiting for the company to provide definitive efficacy signals on the rare genetic disease (RGD) program before...
-
Tracon's Promising Tumor Treatments Make The Stock A Buy
Friday, August 19, 2016 - 10:58am | 375Read More...The promising efficacy of its tumor treatment earns TRACON Pharmaceuticals Inc (NASDAQ: TCON) a Buy rating and $15 price target from BTIG. Tracon's lead compound, TRC105 (an anti-endoglin antibody) has generated promising efficacy in a variety of solid tumors, including HCC, RCC and angiosarcoma...
-
Ophthotech's Fovista Has Potential To Break Through The 'Therapeutic Ceiling' Of Anti-VEGF Therapies
Friday, August 19, 2016 - 10:48am | 401Read More...BTIG’s Ling Wang believes Ophthotech Corp (NASDAQ: OPHT)'s Fovista has the potential to “break through the therapeutic ceiling of current anti-VEGF therapies.” Wang initiated coverage of the company with a Buy rating and price target of $92. Key Catalysts “We view the...
-
Expect Merrimack Pharma Shares To Be Range-Bound For The Near Term
Friday, August 19, 2016 - 9:22am | 296Read More...The sales ramp-up of Merrimack Pharmaceuticals Inc’s (NASDAQ: MACK) lead compound, ONIVYDE, is expected to be gradual in the current indication, BTIG’s Ling Wang said in a report. He reinitiated coverage of the company with a Neutral rating. Slow Sales Ramp ONIVYDE was approved in...
-
Acceleron Has 2 Phase III Trials With Good Chance Of Success; BTIG Initiates Stock At Buy
Friday, August 19, 2016 - 9:11am | 278Read More...Acceleron Pharma Inc (NASDAQ: XLRN) has two ongoing Phase III trials of luspatercept in lower-risk MDS and beta thalassemia, both of which have a 60 percent probability of success, BTIG’s Ling Wang said in a report. He reinitiated coverage of the company with a Buy rating and a price target...
-
Why Oppenheimer Still Thinks Rockwell Medical Could Double
Wednesday, October 21, 2015 - 4:29pm | 293Read More...Oppenheimer reiterated an Outperform rating and $26.00 price target on shares of Rockwell Medical Inc (NASDAQ: RMTI). In a report issued Tuesday, analysts previewed the upcoming American Society of Nephrology (ASN) Kidney Week, and assured that “Data Continues to Support Triferic Long-...
-
35 Stock Ideas Oppenheimer Analysts Love Right Now
Saturday, October 17, 2015 - 10:11pm | 1463Read More...Oppenheimer just released its 35 top stock ideas for October and November. Here’s a rundown of the full list with analyst commentary included. 1. Turtle Beach Corp (NASDAQ: HEAR) Analyst Sean McGowan sees two drivers of the stock: the “resurgence in video games” and the rollout of...
-
8 Oppenheimer Analysts Choose Their Favorite Healthcare Stocks
Tuesday, March 31, 2015 - 12:04pm | 463Read More...In a recent report, Oppenheimer asked analysts that cover different areas of the stock market each to choose his or her single top stock pick in the space based on the company's fundamentals. Here are the stocks that Oppenheimer's eight analysts in the healthcare sector chose as top...
-
UPDATE: Oppenheimer Initiates Coverage On Rockwell Medical On Significant Expected Upside
Wednesday, January 7, 2015 - 9:56am | 117Read More...In a report published Wednesday, Oppenheimer analyst Ling Wang initiated coverage on Rockwell Medical Inc (NASDAQ: RMTI) with an Outperform rating and $24.00 price target. In the report, Oppenheimer noted, “We are initiating coverage on RMTI with an Outperform rating and price target of $24. We...
-
Brean Murray Carret & Co. Maintains Buy Rating On ImmunoGen, Inc. (IMGN)
Monday, April 12, 2010 - 11:35am | 156Read More...Analyst Ling Wang at Brean Murray Carret & Co. has released an update on ImmunoGen, Inc. (NASDAQ: IMGN). The company’s shares have been volatile in the recent past due to speculation of whether partner Genentech/Roche (ADR) (OTC: RHHBY) will be able to file an NDA for T-DM1 in the 3rd line...
-
Brean Murray Carret Reiterates Buy On Immunogen (IMGN)
Thursday, December 10, 2009 - 11:48am | 92Read More...Ling Wang, an analyst at Brean Murray Carret, reiterated a Buy on Immunogen Inc (NASDAQ: IMGN). A 12 month target price of $12 has been derived by summing up the following components of Immunogen’s development programs: the leading product candidate T-DM1 is valued at $350 million, the remaining...
